New DNA sequencing strategy could be vital during disease outbreak

EU-funded scientists have developed a strategy to rapidly identify the genetic properties of virulent strains of bacteria. Such techniques will be essential in responding effectively to an epidemic of a new strain of a disease or a bioterrorist attack.

Thanks to traditional DNA sequencing technologies, researchers have succeeded in sequencing the genomes of over 450 species of bacteria, including representative strains of all major human pathogens. However, this process is extremely slow, and in the case of an outbreak or terrorist attack, scientists need to determine the pathogen's genome as soon as possible so that they can determine which virulence genes or drug resistance genes the bacteria has.

Recently, techniques have been developed which enable scientists to sequence an entire bacterial genome in a matter of hours. However, the finishing steps required to obtain the complete sequence are still very time consuming. In this latest study, scientists in France and Sweden investigated whether enough information to mount a response to an outbreak could be obtained by using a rapidly sequenced, incomplete genome and comparing it to existing genomes for the same species. Their results are published online by the journal Genome Research.

They tested their theory on a strain of Francisella tularensis, a highly infectious bacterium that causes a disease called tularaemia. People catch the disease from the bite of an infected tick, while handling infected animal carcasses or by eating or drinking contaminated food or water. Symptoms include fever, chills, headaches, diarrhoea, muscle and joint pain and progressive weakness. If left untreated, it can be fatal. The scientists chose it for their study because there are strong concerns that it could be genetically manipulated for use as a biological weapon.

"In the context of an outbreak, a quick approach may help to identify immediately the genetic determinants responsible for modified virulence or transmission," explained Dr Bernard La Scola of the University of the Mediterranean in France.

Dr La Scola and his colleagues used rapid sequencing technology to obtain the genome of a strain of F. tularensis taken from a patient suffering from tularaemia. They were able to identify a number of genes linked to virulence as well as a mutation associated with quinolone resistance. The researchers were also able to distinguish their strain from 80 other strains of F. tularensis.

"We demonstrated that this strategy was efficient to detect gene polymorphisms such as a gene modification responsible for antibiotic resistance, and loss of genetic material," commented Dr La Scola.

According to the team, with enough researchers working on the project, the time from DNA extraction to complete genome analysis can be cut to just six weeks. Dr Scola believes that future advances in the software used to analyse and compare genome sequences could cut this time still further.

EU support for the research came from the EU-funded EuroPathoGenomics Network of Excellence, which is funded under the 'Life sciences, genomics and biotechnology for health' thematic area of the Sixth Framework Programme (FP6).

For more information, please visit:
http://www.genome.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...